Adenoid Cystic Carcinoma Research Foundation

06/09/2026

The Spring 2026 ACCRF Research Update is now available! This edition features highlights and new clinical trial data from this year's ASCO annual meeting; a look at Patient Meetings held this year; the most recent Patient Webinar; and the latest updates in clinical trials and research publications. Don't forget to sign up for our newsletter to stay informed on all the latest in ACC research and news!

Email from ACCRF ASCO Highlights, Patient Meetings, the Latest Webinar, and More! ACCRF Research Update - June 2026 For 20 years, ACCRF has been building a global network dedicated to advancing resear

05/21/2026

There's still time to register for our upcoming Patient Meeting in Chicago!

Please join us Saturday, May 30 from 10am-12pm CT in Chicago, IL, USA for a day of community, connection, and education at the the 2026 Midwest ACCRF Patient Meeting.

This unique, in-person event provides a forum for ACC patients to meet, discuss their journeys, and hear about the latest in ACC research and treatment options.

PLEASE NOTE: This is an in-person only event and will not have a virtual option.

To learn more and register for the event, follow the link below. We hope to see you there!

https://lp.constantcontactpages.com/ev/reg/654umy6

05/12/2026

JUST ANNOUNCED: The FDA has granted Breakthrough Therapy Designation to Servier Pharmaceutical’s Emi-Le—a B7-H4-targeting antibody drug conjugate—for ACC patients with solid histology or more aggressive forms of the disease. Breakthrough Therapy Designation is granted when early clinical data suggest a drug may provide substantial clinical benefit for a serious disease, particularly when treatment options are limited. The designation allows for closer collaboration with the FDA and may help accelerate the development and review process for the therapy.

Early results from the Emi-Le clinical trial presented in June of 2025 showed that 56% of ACC patients with aggressive disease had their tumors shrink by 30% or more.

https://tinyurl.com/mvst7hdj

To learn more about Emi-Le and other clinical trials for ACC patients, visit ACCRF's Open Studies webpage and our feature on Emi-Le from 2025 (both linked below). Stay up to date on the latest in ACC news and research by joining our mailing list and following us on social media.

https://linktr.ee/accrf
https://accrf.org/new-b7-h4-adc/
https://accrf.org/treatments/clinical-trials/open-studies/

Emi-Le is a potentially innovative and differentiated antibody drug conjugate (ADC) directed against B7-H4, a well-characterized target in certain cancers including ACC Emi-Le is currently under...

05/11/2026

Our latest ACCRF Patient Webinar: Systemic Therapies in Adenoid cystic carcinoma (ACC) is now available to stream online! Join medical oncologist and ACCRF grantee Dr. Glenn Hanna (Dana Farber Cancer Institute) for a discussion of the latest developments in systemic therapies currently available to ACC patients, and how to chose the best treatment options for your needs.

https://youtu.be/tJo_k0aO8v8?si=_nTYDiOx98m5k9pM

You can find this, along with all previous webinars in our Patient Webinar Archive at https://accrf.org/about-accrf/patient-webinar-archive

ACCRF Patient Webinar 10: Systemic Therapies in Adenoid Cystic Carcinoma (ACC)

04/28/2026

Please join us Saturday, May 30 from 10am-12pm CT in Chicago, IL, USA for a day of community, connection, and education at the the 2026 Midwest ACCRF Patient Meeting.

This unique, in-person event provides a forum for ACC patients to meet, discuss their journeys, and hear about the latest in ACC research and treatment options.

PLEASE NOTE: This is an in-person only event and will not have a virtual option.

To learn more and register for the event, follow the link below. We hope to see you there!

https://lp.constantcontactpages.com/ev/reg/654umy6

04/24/2026

For the 17th year, ACCRF will be participating in the American Society of Clinical Oncology (ASCO) annual meeting in Chicago this May which brings together leading oncologists from around the world to discuss the latest in cancer research and treatment. This year’s conference will feature presentations of new clinical data for two MYB degraders (REM-422 and RGT-61159) from biopharma companies Remix Therapeutics and Rgenta Therapeutics. ACCRF is proud to have collaborated with both these firms, providing preclinical drug screening data from our models that supported the opening of the clinical trials. To stay current on news coming out of ASCO and for all the most up-to-date ACC news, make sure to subscribe to the ACCRF newsletter using the link below!

https://wl.donorperfect.net/weblink/WebLink.aspx?name=E363607&id=3

04/17/2026

ACCRF awards Dr. Piero Dalerba (Hackensack Meridian School of Medicine) a full grant to study "Mechanistic significance and therapeutic eradication of ductal and myoepithelial lineages in human Adenoid Cystic Carcinomas (ACCs)". This work seeks to provide a better understanding of a distinctive biological feature of ACC: that malignant tissue can contain two distinct sub-types of malignant cells (myoepithelial and ductal). The research will also test how effective current ADCs are at targeting both cell types in ACC tumor models.

04/07/2026

A new phase 1 clinical trial for Next Cure's B7-H4 ADC (LNCB74) is now recruiting ACC patients across 14 US sites. This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

03/21/2026

Congratulations to ACCRF Scientific Advisory Board Member Dr. Robert H. Vonderheide (UPenn Abramson Cancer Center) on his election as the new President of the American Association for Cancer Research (AACR). Dr. Vonderheide is an internationally renowned cancer immunotherapy and translational research expert whose work has uncovered the mechanisms of cancer immune surveillance and developed novel immunotherapeutics—such as vaccines, antibody-based therapies, and adoptive T-cell therapies. His expertise and tireless advocacy have helped guide ACCRF’s research efforts. As AACR President, Dr. Vonderheide will succeed Dr. Lillian Siu, who served on the ACCRF Scientific Advisory Board from 2011-2019 and is now an Emeritus Member. The ACC patient community is so fortunate to have benefited from the guidance of these world-leading oncologists.

You can learn more about Dr. Vonderheide’s work in the link below.

https://www.aacr.org/about-the-aacr/newsroom/news-releases/robert-h-vonderheide-md-dphil-faacr-elected-as-american-association-for-cancer-research-president-elect-for-2026-2027/

03/19/2026

Remix Therapeutics recently received FDA Fast Track designation for its drug REM-422, which targets MYB mRNA. Fast Track designation speeds up the development and review of drugs for serious diseases, especially when there are limited treatment options. Drugs in this program get more frequent communication with the FDA and results from their clinical trials may be reviewed faster.

REM-422 is currently being tested in a clinical trial recently named as ARIA (A Study of REM-422 In Adenoid Cystic Carcinoma). Early results presented in October showed that 43% of biomarker-positive ACC patients who took the drug for 6 months or longer had their tumors shrink by 30% or more. To learn more about ARIA and other clinical trials for ACC patients visit ACCRF's Open Studies webpage.

Preliminary Phase 1 Study Results Show Strong Anti-Tumor Activity and Favorable Safety Profile for First-in-Class Small Molecule MYB mRNA Degrader No Approved Treatment Options for Patients with MYB-Driven Solid Tumor Adenoid Cystic Carcinoma   WATERTOWN, Mass., March 19, 2026 – Remix Therapeutic...